Supernus Enterprise Value vs Gross Profit Analysis
SUPN Stock | USD 29.40 0.53 1.84% |
Supernus Pharmaceuticals financial indicator trend analysis is much more than just breaking down Supernus Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Supernus Pharmaceuticals is a good investment. Please check the relationship between Supernus Pharmaceuticals Enterprise Value and its Gross Profit accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
Enterprise Value vs Gross Profit
Enterprise Value vs Gross Profit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Supernus Pharmaceuticals Enterprise Value account and Gross Profit. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Supernus Pharmaceuticals' Enterprise Value and Gross Profit is 0.91. Overlapping area represents the amount of variation of Enterprise Value that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Supernus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Supernus Pharmaceuticals' Enterprise Value and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Enterprise Value of Supernus Pharmaceuticals are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Enterprise Value i.e., Supernus Pharmaceuticals' Enterprise Value and Gross Profit go up and down completely randomly.
Correlation Coefficient | 0.91 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Enterprise Value
Enterprise Value (or EV) is usually referred to as Supernus Pharmaceuticals theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Supernus Pharmaceuticals debt, but would also pocket its cash. Enterprise Value is more accurate representation of Supernus Pharmaceuticals value than its market capitalization because it takes into account all of Supernus Pharmaceuticals existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Supernus Pharmaceuticals minus its cost of goods sold. It is profit before Supernus Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most indicators from Supernus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 19th of April 2024, Issuance Of Capital Stock is likely to grow to about 8.4 M, while Selling General Administrative is likely to drop about 85.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 23.4M | 7.1M | 2.4M | 2.3M | Depreciation And Amortization | 34.0M | 82.6M | 84.9M | 89.1M |
Supernus Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Supernus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Supernus Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 53.8M | 53.7M | 54.4M | 61.7M | 55.5M | 42.6M | |
Total Assets | 1.2B | 1.5B | 1.7B | 1.7B | 1.4B | 1.5B | |
Short Long Term Debt Total | 375.6M | 390.3M | 420.6M | 438.0M | 41.5M | 39.5M | |
Other Current Liab | 3.2M | 40.0M | 65.0M | 139.8M | 279.9M | 293.9M | |
Total Current Liabilities | 160.6M | 245.1M | 315.4M | 688.0M | 290.2M | 154.7M | |
Total Stockholder Equity | 595.4M | 744.9M | 815.9M | 886.2M | 921.5M | 967.6M | |
Property Plant And Equipment Net | 38.3M | 37.8M | 17.0M | 15.2M | 42.5M | 44.7M | |
Net Debt | 194.2M | 101.7M | 217.1M | 344.8M | (33.5M) | (31.9M) | |
Retained Earnings | 199.5M | 326.5M | 379.9M | 481.2M | 482.6M | 506.7M | |
Accounts Payable | 10.1M | 78.9M | 117.7M | 96.3M | 2.0M | 1.9M | |
Cash | 181.4M | 288.6M | 203.4M | 93.1M | 75.1M | 116.1M | |
Non Current Assets Total | 687.6M | 873.7M | 1.1B | 968.4M | 915.9M | 961.7M | |
Non Currrent Assets Other | 615K | 8.0M | (36.1M) | (10.0M) | 8.5M | 8.9M | |
Cash And Short Term Investments | 347.1M | 422.5M | 339.7M | 461.3M | 254.9M | 201.2M | |
Net Receivables | 87.3M | 140.9M | 148.9M | 165.5M | 144.2M | 151.4M | |
Common Stock Total Equity | 51K | 52K | 53K | 54K | 62.1K | 40.8K | |
Short Term Investments | 165.7M | 133.9M | 136.2M | 368.2M | 179.8M | 98.1M | |
Liabilities And Stockholders Equity | 1.2B | 1.5B | 1.7B | 1.7B | 1.4B | 1.5B | |
Non Current Liabilities Total | 404.3M | 514.1M | 557.9M | 128.3M | 197.3M | 179.2M | |
Inventory | 26.6M | 48.3M | 86.0M | 91.5M | 77.4M | 81.3M | |
Other Current Assets | 11.6M | 18.7M | 27.0M | 15.8M | 16.7M | 8.5M | |
Other Stockholder Equity | 388.4M | 409.3M | 434.3M | 408.1M | 439.5M | 279.8M | |
Total Liab | 564.9M | 759.2M | 873.3M | 816.3M | 487.5M | 333.9M | |
Property Plant And Equipment Gross | 38.3M | 37.8M | 33.4M | 28.2M | 28.9M | 30.4M | |
Total Current Assets | 472.6M | 630.4M | 601.6M | 734.2M | 493.1M | 305.3M | |
Accumulated Other Comprehensive Income | 7.4M | 9.0M | 1.5M | (3.2M) | (593K) | (563.4K) | |
Intangible Assets | 24.8M | 442.3M | 784.7M | 702.5M | 599.9M | 629.9M | |
Common Stock | 51K | 52K | 53K | 54K | 55K | 42.0K | |
Other Liab | 28.7M | 123.8M | 137.4M | 92.3M | 106.2M | 111.5M | |
Other Assets | 32.7M | 259.7M | 13.9M | 10.9M | 12.5M | 11.9M | |
Long Term Debt | 329.5M | 345.2M | 361.8M | 379.3M | 436.1M | 457.9M | |
Property Plant Equipment | 17.1M | 37.8M | 52.3M | 44.1M | 50.7M | 53.2M | |
Net Tangible Assets | 570.6M | 302.6M | (86.4M) | 66.7M | 76.7M | 72.9M | |
Good Will | 24.8M | 77.9M | 117.5M | 117.0M | 134.6M | 141.3M | |
Retained Earnings Total Equity | 199.5M | 326.5M | 379.9M | 481.2M | 553.4M | 581.1M | |
Capital Surpluse | 388.4M | 409.3M | 434.3M | 408.1M | 469.3M | 352.1M |
Currently Active Assets on Macroaxis
When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Supernus Stock analysis
When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.02 | Revenue Per Share 11.14 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0056 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.